<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31881489</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3254</ISSN><JournalIssue CitedMedium="Internet"><Volume>188</Volume><PubDate><Year>2020</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>European journal of medicinal chemistry</Title><ISOAbbreviation>Eur J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses.</ArticleTitle><Pagination><StartPage>112007</StartPage><MedlinePgn>112007</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2019.112007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0223-5234(19)31164-X</ELocationID><Abstract><AbstractText>Today, there are no medicines to treat enterovirus and rhinovirus infections. In the present study, a series of novel pleconaril derivatives with substitutions in the isoxazole and phenyl rings was synthesized and evaluated for their antiviral activity against a panel of pleconaril-sensitive and -resistant enteroviruses. Studies of the structure-activity relationship demonstrate the crucial role of the N,N-dimethylcarbamoyl group in the isoxazole ring for antiviral activity against pleconaril-resistant viruses. In addition, one or two substituents in the phenyl ring directly impact on the spectrum of antienteroviral activity. The 3-(3-methyl-4-(3-(3-N,N-dimethylcarbamoyl-isoxazol-5-yl)propoxy)phenyl)-5-trifluoromethyl-1,2,4-oxadiazole 10g was among the compounds exhibiting the strongest activity against pleconaril-resistant as well as pleconaril-susceptible enteroviruses with IC<sub>50</sub> values from 0.02 to 5.25&#xa0;&#x3bc;M in this series. Compound 10g demonstrated markedly less CYP3A4 induction than pleconaril, was non-mutagenic, and was bioavailable after intragastric administration in mice. These results highlight compound 10g as a promising potential candidate as a broad spectrum enterovirus and rhinovirus inhibitor for further preclinical investigations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Egorova</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, 33-2 Leninsky Prospect, Moscow, 119071, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazakova</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, 33-2 Leninsky Prospect, Moscow, 119071, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahn</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Jena University Hospital, Department of Medical Microbiology, Section Experimental Virology, Hans-Kn&#xf6;ll-Strasse 2, Jena, 07745, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekins</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makarov</LastName><ForeName>Vadim</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, 33-2 Leninsky Prospect, Moscow, 119071, Russia. Electronic address: makarov@inbi.ras.ru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidtke</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Jena University Hospital, Department of Medical Microbiology, Section Experimental Virology, Hans-Kn&#xf6;ll-Strasse 2, Jena, 07745, Germany. Electronic address: michaela.schmidtke@med.uni-jena.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 TR001718</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Med Chem</MedlineTA><NlmUniqueID>0420510</NlmUniqueID><ISSNLinking>0223-5234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010069">Oxadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010080">Oxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>9H4570Q89D</RegistryNumber><NameOfSubstance UI="C115201">pleconaril</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010069" MajorTopicYN="N">Oxadiazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010080" MajorTopicYN="N">Oxazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antivirals</Keyword><Keyword MajorTopicYN="N">CYP3A4 induction</Keyword><Keyword MajorTopicYN="N">Capsid-binding inhibitor</Keyword><Keyword MajorTopicYN="N">Coxsackie B3 virus</Keyword><Keyword MajorTopicYN="N">Drug design/discovery</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">Resistance</Keyword><Keyword MajorTopicYN="N">Rhinovirus</Keyword><Keyword MajorTopicYN="N">Structure-activity relationship analysis</Keyword></KeywordList><CoiStatement>Declaration of competing interest Sean Ekins is CEO of Collaborations Pharmaceuticals, Inc. Vadim Makarov, Michaela Schmidtke and Sean Ekins are co-inventors on a US provisional patent relating to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31881489</ArticleId><ArticleId IdType="mid">NIHMS1547532</ArticleId><ArticleId IdType="pmc">PMC7002245</ArticleId><ArticleId IdType="doi">10.1016/j.ejmech.2019.112007</ArticleId><ArticleId IdType="pii">S0223-5234(19)31164-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miller EK, Mackay IM. From sneeze to wheeze: what we know about rhinovirus Cs, J. Clin. Virol 57 (2013) 291&#x2013;299. 10.1016/j.jcv.2013.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2013.04.015</ArticleId><ArticleId IdType="pubmed">23714395</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnick JL, Poliovirus and other enteroviruses, in: Evans AS, Kaslow RA (Eds.), Viral infections of humans: epidemiology and control, Plenum Publishing, New York, 1997, pp. 583&#x2013;663.</Citation></Reference><Reference><Citation>Pallansch M, Roos R, Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses In: Knipe D, Howley P (Eds.), Fields Virology. Lippincott Williams Wilkins, Philadelphia, 2007, pp. 839&#x2013;894.</Citation></Reference><Reference><Citation>Gern JE. The ABCs of rhinoviruses, wheezing, and asthma, J. Virol 84 (2010) 7418&#x2013;7426. 10.1128/JVI.02290-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02290-09</ArticleId><ArticleId IdType="pmc">PMC2897627</ArticleId><ArticleId IdType="pubmed">20375160</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG. Rhinovirus and the lower respiratory tract, Rev. Med. Virol 14 (2004) 17&#x2013;31. 10.1002/rmv.406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.406</ArticleId><ArticleId IdType="pmc">PMC7169234</ArticleId><ArticleId IdType="pubmed">14716689</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse WW, Lemanske RF Jr., Gern JE, The role of viral respiratory infections in asthma and asthma exacerbations, Lancet. 376 (2010) 826&#x2013;834. 10.1016/S0140-6736(10)61380-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61380-3</ArticleId><ArticleId IdType="pmc">PMC2972660</ArticleId><ArticleId IdType="pubmed">20816549</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson DJ, Johnston SL, The role of viruses in acute exacerbations of asthma, J. Allergy Clin. Immunol 125 (2010) 1178&#x2013;1187. 10.1016/j.jaci.2010.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2010.04.021</ArticleId><ArticleId IdType="pmc">PMC7172767</ArticleId><ArticleId IdType="pubmed">20513517</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut HJ, Lacroix C, De Palma AM, Franco D, Decramer M, Neyts J, Toward antiviral therapy/prophylaxis for rhinovirus-induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies, Rev. Med. Virol 26 (2016) 21&#x2013;33. 10.1002/rmv.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv</ArticleId><ArticleId IdType="pmc">PMC7169185</ArticleId><ArticleId IdType="pubmed">26388447</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, Poliomyelitis. https://www.who.int/immunization/diseases/poliomyelitis/en/, 2017.  (accessed
11 June 2019).</Citation></Reference><Reference><Citation>Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY, Enterovirus 71 infection and vaccines, Clin. Exp. Vaccine Res. 6 (2017) 4&#x2013;14. 10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>World Organisation for Animal Health, Foot &amp; Mouth disease (FMD). https://www.oie.int/en/animal-health-in-the-world/animal-diseases/foot-and-mouth-disease/, 2018.  (accessed
18 December 2019).</Citation></Reference><Reference><Citation>Rossmann MG, He Y, Kuh RJ, Picornavirus-receptor interactions, Trends Microbiol. 10 (2002) 324&#x2013;331. 10.1016/S0966-842X(02)02383-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0966-842X(02)02383-1</ArticleId><ArticleId IdType="pubmed">12110211</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Hill MG, Klose T, Chen Z, Watters K, Bochkov YA, Jiang W, Palmenberg AC, Rossmann MG, Atomic structure of a rhinovirus C, a virus species linked to severe childhood asthma, Proc. Natl. Acad. Sci. USA 113 (2016) 8997&#x2013;9002. 10.1073/pnas.1606595113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1606595113</ArticleId><ArticleId IdType="pmc">PMC4987780</ArticleId><ArticleId IdType="pubmed">27511920</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A, Ekins S, Schmidtke M, Makarov V, Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses, Eur. J. Med. Chem 178 (2019) 606&#x2013;622. 10.1016/j.ejmech.2019.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.06.008</ArticleId><ArticleId IdType="pmc">PMC8194503</ArticleId><ArticleId IdType="pubmed">31226653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T, Collett MS, Pevear DC, VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds, J. Virol 78 (2004) 3663&#x2013;3674. 10.1128/jvi.78.7.3663-3674.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.78.7.3663-3674.2004</ArticleId><ArticleId IdType="pmc">PMC371056</ArticleId><ArticleId IdType="pubmed">15016887</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarov VA, Braun H, Richter M, Riabova OB, Kirchmair J, Kazakova ES, Seidel N, Wutzler P, Schmidtke M, Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses, ChemMedChem. 10 (2015) 1629&#x2013;1634. 10.1002/cmdc.201500304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201500304</ArticleId><ArticleId IdType="pmc">PMC4600222</ArticleId><ArticleId IdType="pubmed">26260222</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun H, Kirchmair J, Williamson MJ, Makarov VA, Riabova OB, Glen RC, Sauerbrei A, Schmidtke M, Molecular mechanism of a specific capsid binder resistance caused by mutations outside the binding pocket, Antiviral Res. 123 (2015) 138&#x2013;145. 10.1016/j.antiviral.2015.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.09.009</ArticleId><ArticleId IdType="pubmed">26391975</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M, Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials, Clin. Infect Dis. 36 (2003) 1523&#x2013;1532. 10.1086/375069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/375069</ArticleId><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Genetic Engineering &amp; Biotechnology News, Aviragen Antiviral Drug Vapendavir Fails Phase IIb Study in Asthma Patients. https://www.genengnews.com/topics/drug-discovery/aviragen-antiviral-drug-vapendavir-fails-phase-iib-study-in-asthma-patients/, 2017.  (accessed
22 October 2019).</Citation></Reference><Reference><Citation>Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M, Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model, J. Infect. Dis, 215 (2017) 335&#x2013;343. 10.1093/infdis/jiw542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw542</ArticleId><ArticleId IdType="pmc">PMC5393058</ArticleId><ArticleId IdType="pubmed">27932608</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarov VA, Riabova OB, Granik VG, Wutzler P, Schmidtke M, Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication, J. Antimicrob. Chemother 55 (2005) 483&#x2013;488. 10.1093/jac/dki055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki055</ArticleId><ArticleId IdType="pubmed">15743897</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA, New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3, Antiviral Res. 81 (2009) 56&#x2013;63. 10.1016/j.antiviral.2008.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.09.002</ArticleId><ArticleId IdType="pubmed">18840470</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidtke M, Schnittler U, Jahn B, Dahse H, Stelzner A, A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1, J. Virol. Methods 95 (2001) 133&#x2013;43. 10.1016/s0166-0934(01)00305-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0166-0934(01)00305-6</ArticleId><ArticleId IdType="pubmed">11377720</ArticleId></ArticleIdList></Reference><Reference><Citation>Nain M, Hinder F, Gong JH, Schmidt A, Bender A, Sprenger H, Gemsa D, Tumor necrosis factor-alpha production of influenza A virus-infected macro-phages and potentiating effect of lipopolysaccharides, J. Immunol 145 (1990), 1921&#x2013;1928.</Citation><ArticleIdList><ArticleId IdType="pubmed">2391423</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidtke M, Hammerschmidt E, Sch&#xfc;ler S, Zell R, Birch-Hirschfeld E, Makarov VA, Riabova OB, Wutzler P, Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment, J. Antimicrob. Chemother 56 (2005) 648&#x2013;656. 10.1093/jac/dki263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki263</ArticleId><ArticleId IdType="pubmed">16150864</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, De Clercq E, Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds, J. Virol. Methods 20 (1988), 309&#x2013;321. 10.1016/0166-0934(88)90134-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-0934(88)90134-6</ArticleId><ArticleId IdType="pubmed">2460479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C, Li AP, Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog, Chem. Biol. Interact 134 (2001) 271&#x2013;281. 10.1016/s0009-2797(01)00162-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0009-2797(01)00162-4</ArticleId><ArticleId IdType="pubmed">11336975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zysman-Colman E, Arias K, Siegel JS, Synthesis of arylbromides from arenes and N-bromosuccinimide (NBS) in acetonitrile &#x2013; A convenient method for aromatic bromination, Can. J. Chem 87 (2009) 440&#x2013;447. 10.1139/V08-176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/V08-176</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman L, Shechter H, Dimethylformamide as a Useful Solvent in Preparing Nitriles from Aryl Halides and Cuprous Cyanide; Improved Isolation Techniques, J. Org. Chem 26 (1961) 2522&#x2013;2524. 10.1021/jo01351a092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jo01351a092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi C, Tabata Y, Yamakawa T, Matsuhira T, Watanabe N, Kubota N, Kaneda K, inventors; Meiji Seika Pharma Co Ltd, assignee. PDE4 inhibitor. US patent 2016/0159783 A1 June 9 2016.</Citation></Reference><Reference><Citation>Steinkopf W, Jurgens B, Uber die Konstitution der aci-Nitrokorper, J. Prakt. Chem 84 (1911) 686&#x2013;713.</Citation></Reference><Reference><Citation>Kozikowski AP, Adamcz M, Methods for the stereoselective cis-cyanohydroxylation and - carboxyhydroxylation of olefins, J. Org. Chem 48 (1983) 366&#x2013;372. 10.1021/jo00151a017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jo00151a017</ArticleId></ArticleIdList></Reference><Reference><Citation>Said SB, Skar&#x17e;ewski J, M&#x142;chowski J, Oxidative Conversion of Aldoximes into Carboxylic Acid Esters, Synth. Commun 22 (1992) 1851&#x2013;1862. 10.1080/00397919208021316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00397919208021316</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest HS, Walker J, Chemotherapeutic agents of the sulphone type. Part V. 2: 5-Disubstituted derivatives of pyridine, J. Chem. Soc (1948) 1935&#x2013;1945. 10.1039/JR9480001939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/JR9480001939</ArticleId><ArticleId IdType="pubmed">18106013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran U, Mital A, Bharatam PV, Khanna S, Rao PR, Srinivasan K, Kumar R, Chawla HP, Kaul CL, Raichur S, Chakrabarti R, Studies on some glitazones having pyridine as the linker unit, Bioorg. Med. Chem 12 (2004) 655&#x2013;662. 10.1016/j.bmc.2003.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2003.11.027</ArticleId><ArticleId IdType="pubmed">14759726</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H, A simple method of estimating fifty percent endpoints, Am. J. Epidemiol 27 (1938) 493&#x2013;497 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Quillardet P, Hofnung M, The SOS chromotest: a review, Mutat Res. 7 (1993) 235&#x2013;279. 10.1016/0165-1110(93)90019-j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-1110(93)90019-j</ArticleId><ArticleId IdType="pubmed">7692273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>